XML 57 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Details Narrative 2) - USD ($)
1 Months Ended 3 Months Ended
Jun. 30, 2013
May 11, 2013
May 31, 2013
May 31, 2012
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Prepaid expenses - current         $ 368,594   $ 405,960
Recognition period of unamortized costs         2 years 8 months 12 days    
SCI - Warrants [Member]              
Exercise price of warrants (in dollars per share)     $ 2.01        
Warrants granted to purchase common stock (shares)     850,000        
Non-cash compensation         $ 0 $ 38,517  
Unamortized costs of warrants         $ 64,449    
Forfeited warrants granted to purchase common stock (shares)     833,000        
Recognition period of unamortized costs         3 months    
SCI - Warrants [Member] | Tranche One [Member]              
Fair value of grant $ 405,066            
Non-cash compensation 405,066            
Vesting date of warrants   Jun. 30, 2013          
Expected term   5 years          
Volatility rate   45.89%          
Risk free rate   1.12%          
Dividend yield   0.00%          
Vested warrants granted to purchase common stock (shares)   283,333          
SCI - Warrants [Member] | Tranche Two [Member]              
Fair value of grant $ 462,196            
Expected term 5 years            
Volatility rate 45.84%            
Risk free rate 1.41%            
Dividend yield 0.00%            
Vested warrants granted to purchase common stock (shares) 283,333            
SCI - Warrants [Member] | Tranche Three [Member]              
Description of shares to be vested  

283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will not occur before May 2017.

         
Warrants - Unaffiliated Entity [Member] [Member]              
Exercise price of warrants (in dollars per share)       $ 2.57      
Fair value of grant       $ 1,532,228      
Warrants granted to purchase common stock (shares)       1,300,000      
Prepaid expenses - current         $ 64,449    
Non-cash compensation         $ 64,449 $ 64,449  
Expected term       5 years      
Volatility rate       44.71%      
Risk free rate       0.74%      
Dividend yield       0.00%